Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
13 EUR | 0,00% | -0,76% | -5,11% |
28/06 | Johnson & Johnson annonce des résultats "positifs" dans une étude de stade avancé sur la myasthénie grave | MT |
28/06 | Le combo Rybrevant de l'unité J&J obtient l'approbation de l'UE | MT |
Métier
- produits pharmaceutiques (55,4%) : médicaments destinés au traitement des maladies cardio-vasculaires, oncologiques, infectieuses, gastro-intestinales, immunitaires, neurologiques, dermatologiques, etc. ;
- produits et équipements médicaux (28,9%) : systèmes de diagnostic, produits orthopédiques et gynécologiques, matériel chirurgical, etc. destinés aux professionnels de la santé ;
- produits de grande consommation (15,7%) : médicaments OTC (marques Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette, etc.), produits de santé et de beauté (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena et OGX), de soins pour bébés (Johnson's et Aveeno Baby), de soins bucco-dentaires (Listerine), d'hygiène féminine (Stayfree and Carefree et o.b.), de soins des plaies (Band-Aid et Neosporin), etc.
A fin 2022, Johnson & Johnson dispose de 89 sites de production implantés aux Etats-Unis (28), en Amérique du Nord (9), en Europe (27), en Afrique et Asie-Pacifique (25).
La répartition géographique du CA est la suivante : Etats-Unis (51,2%), Europe (24,7%), Asie-Pacifique et Afrique (17,7%) et autres (6,4%).
Nombre d'employés: 131 900
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Innovative Medicine
64,3
%
| 52 563 | 55,4 % | 54 759 | 64,3 % | +4,18% |
MedTech
35,7
%
| 27 427 | 28,9 % | 30 400 | 35,7 % | +10,84% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
54,5
%
| 48 580 | 51,2 % | 46 444 | 54,5 % | -4,40% |
Europe
24,0
%
| 23 449 | 24,7 % | 20 410 | 24,0 % | -12,96% |
Asia-Pacific, Africa
16,2
%
| 16 789 | 17,7 % | 13 756 | 16,2 % | -18,07% |
Western Hemisphere Excluding United States
5,3
%
| 6 125 | 6,5 % | 4 549 | 5,3 % | -25,73% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01/01/89 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01/01/98 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/11/19 |
William Hait
CTO | Chief Tech/Sci/R&D Officer | 74 | 01/01/07 |
Jessica Moore
IRC | Investor Relations Contact | - | 01/11/21 |
Michael Bzdak
PRN | Corporate Officer/Principal | - | - |
Jonathan Sheh
PRN | Corporate Officer/Principal | - | - |
Neil Ackerman
PRN | Corporate Officer/Principal | 47 | 01/01/19 |
Caroline Tillett
PRN | Corporate Officer/Principal | 52 | - |
General Counsel | 53 | 01/01/06 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 19/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22/10/09 |
Hubert Joly
BRD | Director/Board Member | 64 | 05/12/19 |
Mark McClellan
BRD | Director/Board Member | 60 | 15/10/13 |
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01/01/89 |
Darius Adamczyk
BRD | Director/Board Member | 58 | 15/02/22 |
Eugene Woods
BRD | Director/Board Member | 59 | 30/11 |
Mark Weinberger
BRD | Director/Board Member | 62 | 05/12/19 |
Nadja West
BRD | Director/Board Member | 63 | 03/12/20 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 3 119 799 183 | 2 404 640 893 ( 77,08 %) | 713 120 000 ( 22,86 %) | 77,08 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
KENVUE INC. 9,52% | 182 329 550 | 9,52% | 3 518 960 315 $ |
ILLUMINA, INC. 0,51% | 810 170 | 0,51% | 84 484 528 $ |
2 449 183 | 4,18% | 68 944 501 $ | |
NANOBIOTIX 11,93% | 5 623 816 | 11,93% | 39 591 665 $ |
814 586 | 0,45% | 32 591 586 $ | |
MEIRAGTX HOLDINGS PLC 10,33% | 6 641 064 | 10,33% | 32 541 214 $ |
CONTINEUM THERAPEUTICS, INC. 10,42% | 1 979 173 | 10,42% | 30 320 930 $ |
CVRX, INC. 19,00% | 4 103 430 | 19,00% | 28 518 839 $ |
IDORSIA LTD 5,07% | 9 581 882 | 5,07% | 27 551 264 $ |
357 939 | 0,70% | 23 767 150 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Medical Specialties
| |
Pharmaceuticals: Major
| |
AMO Holdings, Inc.
AMO Holdings, Inc. Electronic ComponentsElectronic Technology Part of Johnson & Johnson, AMO Holdings, Inc. is an American company that manufactures surgical medical devices and lens. The company is located in the US. |
Electronic Components
|
Animas LLC
Animas LLC Medical SpecialtiesHealth Technology Animas LLC manufactures and distributes external insulin pumps for diabetes patients. The company was founded on November 5, 1996 and is headquartered in West Chester, PA. |
Medical Specialties
|
Pharmaceuticals: Major
| |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. |
Pharmaceuticals: Major
|
Johnson & Johnson Holdco (NA), Inc.
Johnson & Johnson Holdco (NA), Inc. Household/Personal CareConsumer Non-Durables Johnson & Johnson Consumer, Inc. manufactures health and skin care products. It offers wide variety of lotion, moisturizing cream, baby wash, shampoo and conditioner, baby powder and bath, hand and face wipes, soap, baby oil and cologne. The company was founded on March 8, 2016 and is headquartered in Skillman, NJ. |
Household/Personal Care
|
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. |
Pharmaceuticals: Major
|
BioMedical Enterprises, Inc.
BioMedical Enterprises, Inc. Medical SpecialtiesHealth Technology BioMedical Enterprises, Inc. designs, manufactures and markets memory metal implants. It offers products: intramedullary fixation which includes hammerLock and hammerSplint and staple fixation which includes speed, step OSStaple and step BOSS. The company was founded by William Casey Fox in 1991 and is headquartered in San Antonio, TX. |
Medical Specialties
|
Secteur
Ventes par activité
Ventes par région
Varia. 1 janv. | Capi. | |
---|---|---|
+55,32% | 815 Md | |
+44,05% | 641 Md | |
+13,56% | 314 Md | |
+10,68% | 303 Md | |
+16,57% | 242 Md | |
+13,31% | 218 Md | |
+8,48% | 168 Md | |
-2,81% | 159 Md | |
+0,20% | 120 Md |
- Bourse
- Actions
- Action JNJ
- Action JNJ0
- Société Johnson & Johnson